论文部分内容阅读
美国FDA于2011年5月5日批准诺华(Novartis)药业公司的Afinitor(everolimus)用于治疗不能手术切除或已经扩散的胰腺进行性神经内分泌瘤(PNET)。据了解,在过去将近30年里美国未曾批准过针对该类疾病的药物。
On May 5, 2011, the FDA approved Afinitor (everolimus) from Novartis Pharmaceuticals for the treatment of pancreatic progressive neuroendocrine tumors (PNET) that are not surgically resealable or have proliferated. It is understood that the United States has not approved drugs for these diseases in the past 30 years or so.